Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2017Blood Cancer JournalOpen Access

Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAziz NazhaMSMikkael A. SekeresRKRami S. Komrokji

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nazha et al. (2017) studied this question.

synapsesocial.com/papers/6a851fdc0743ff3319d979bchttps://doi.org/10.1038/s41408-017-0018-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes1997 · 4,480 citations
  2. 2Predicting outcome of patients with myelodysplastic syndromes after failure of azacitidine: validation of the North American MDS consortium scoring system2016 · 16 citations
  3. 3The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure2016 · 38 citations
  4. 4Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group2011 · 554 citations
  5. 5Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure2011 · 485 citations